Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how genomic profiling improves risk assessment, guides treatment intensity, and reveals mechanisms of resistance in multiple myeloma across disease stages at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Mark Bustoros, MD, discusses how...